Goldman Sachs Group Inc Atossa Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$706 Billion
Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 334,953 shares of ATOS stock, worth $348,351. This represents 0.0% of its overall portfolio holdings.

Number of Shares

334,953

Previous 187,927 78.24%

Holding current value

$348,351

Previous $125,000 122.4%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.59 - $1.03 $86,745 - $151,436	147,026 Added 78.24%	334,953 $278,000
Q1 2025 May 09, 2025	SELL	$0.67 - $1.01 $105,143 - $158,500	-156,931 Reduced 45.51%	187,927 $125,000
Q4 2024 Feb 11, 2025	BUY	$0.94 - $1.62 $89,986 - $155,082	95,730 Added 38.43%	344,858 $324,000
Q3 2024 Nov 14, 2024	BUY	$1.09 - $1.52 $159,644 - $222,623	146,463 Added 142.66%	249,128 $378,000
Q2 2024 Aug 13, 2024	SELL	$1.03 - $2.1 $541,665 - $1.1 Million	-525,889 Reduced 83.67%	102,665 $122,000
Q1 2024 May 15, 2024	BUY	$0.8 - $1.89 $502,843 - $1.19 Million	628,554 New	628,554 $1.13 Million
Q2 2022 May 14, 2024	BUY	$0.85 - $1.28 $54,632 - $82,269	64,273 New	64,273 $70,000
Q2 2022 Aug 15, 2022	SELL	$0.85 - $1.28 $32,340 - $48,701	-38,048 Reduced 37.18%	64,273 $70,000
Q1 2022 May 16, 2022	SELL	$1.11 - $1.74 $174,863 - $274,110	-157,535 Reduced 60.62%	102,321 $128,000
Q4 2021 Feb 14, 2022	BUY	$1.6 - $3.27 $83,659 - $170,978	52,287 Added 25.19%	259,856 $416,000
Q3 2021 Nov 10, 2021	BUY	$2.89 - $6.4 $599,874 - $1.33 Million	207,569 New	207,569 $676,000

Others Institutions Holding ATOS

# of Institutions

Shares Held

28.6M

Call Options Held

12.7K

Put Options Held

92.9K

View Full List

About ATOSSA THERAPEUTICS, INC.

Ticker ATOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,624,000
Market Cap $132M
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...

More about ATOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Atossa Therapeutics, Inc. Transaction History